These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 26988074

  • 1. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N, Merlen C, Bonnefoy A, St-Louis J, Rivard GE.
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [Abstract] [Full Text] [Related]

  • 2. Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise.
    Merlen C, Zourikian N, Bonnefoy A, Dubé E, Thibeault C, St-Louis J, Rivard GE.
    Blood Coagul Fibrinolysis; 2018 Nov; 29(7):626-635. PubMed ID: 30036280
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
    Kepa S, Horvath B, Reitter-Pfoertner S, Schemper M, Quehenberger P, Grundbichler M, Heistinger M, Neumeister P, Mannhalter C, Pabinger I.
    Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
    Chen ZP, Li PJ, Li G, Tang L, Zhen YZ, Wu XY, Cheng XL, Luke KH, Blanchette VS, Poon MC, Ding QL, Wu RH.
    Chin Med J (Engl); 2018 Aug 05; 131(15):1780-1785. PubMed ID: 29848837
    [Abstract] [Full Text] [Related]

  • 7. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
    Ogiwara K, Swystun LL, Paine AS, Kepa S, Choi SJ, Rejtö J, Hopman W, Pabinger I, Lillicrap D.
    J Thromb Haemost; 2021 Mar 05; 19(3):654-663. PubMed ID: 33219619
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
    Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, Ciavarella N, De Rosa V, Arter A.
    Thromb Haemost; 1993 Aug 02; 70(2):270-2. PubMed ID: 8236134
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A, Windyga J, Batorova A.
    Thromb Res; 2011 Mar 02; 127(3):247-53. PubMed ID: 21220152
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia.
    Kumar R, Bouskill V, Schneiderman JE, Pluthero FG, Kahr WH, Craik A, Clark D, Whitney K, Zhang C, Rand ML, Carcao M.
    Thromb Haemost; 2016 Jun 02; 115(6):1120-8. PubMed ID: 26917411
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
    Dmoszynska A, Hellmann A, Baglin T, O'Shaugnessy D, Trelinski J, Kuliczkowski K, Kloczko J, Hay C, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C.
    Haemophilia; 2011 Mar 02; 17(2):185-90. PubMed ID: 21070496
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun 02; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N, Oleshko O, Werwitzke S, Solecka-Witulska B, Kannicht C, Tiede A.
    Blood; 2021 Feb 25; 137(8):1072-1081. PubMed ID: 32877516
    [Abstract] [Full Text] [Related]

  • 19. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group.
    J Thromb Haemost; 2023 May 25; 21(5):1123-1134. PubMed ID: 36775768
    [Abstract] [Full Text] [Related]

  • 20. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.
    J Thromb Haemost; 2019 Jul 25; 17(7):1085-1096. PubMed ID: 31038793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.